Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology's Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $10.1 million for Q2 2025.

• In Q2 2025, Current Deferred Revenue fell 39.47% year-over-year to $10.1 million; the TTM figure through Jun 2025 stood at $10.1 million (down 39.47% YoY), while the FY2024 annual figure was $12.6 million, down 80.5% from the prior year.
• Current Deferred Revenue came in at $10.1 million for Q2 2025 at Vir Biotechnology, down from $11.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $262.9 million in Q1 2021 to a low of $10.1 million in Q2 2025.
• A 5-year average of $48.0 million and a median of $16.2 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 5148.08% in 2021 and plunged 94.1% in 2022, its largest moves.
• Vir Biotechnology's Current Deferred Revenue stood at $98.2 million in 2021, then plunged by 84.2% to $15.5 million in 2022, then surged by 317.95% to $64.9 million in 2023, then plunged by 80.5% to $12.6 million in 2024, then fell by 20.07% to $10.1 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $10.1 million, $11.9 million, and $12.6 million for Q2 2025, Q1 2025, and Q4 2024 respectively.

Peer Comparison